Korean PNH patients monitored on new add-on drug danicopan
NCT ID NCT07457151
First seen Mar 22, 2026 · Last updated May 10, 2026 · Updated 3 times
Summary
This study is for people in Korea with a rare blood disease called PNH. It looks at how safe and effective the drug Danicopan is when added to their usual treatment. About 8 participants will be followed in regular clinic visits. The goal is to confirm the drug's known safety and see if it helps improve blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBusan, South Korea
-
Research Site
NOT_YET_RECRUITINGDaegu, South Korea
-
Research Site
NOT_YET_RECRUITINGHwasun-gun, South Korea
-
Research Site
NOT_YET_RECRUITINGSeoul, South Korea
Conditions
Explore the condition pages connected to this study.